Diality has announced successful completion of the first patient treatment with the Moda-flx haemodialysis system in collaboration with North America Research Institute at Ontario-Holt Dialysis Center in Ontario, California.
The Moda-flx haemodialysis system is designed to empower kidney care professionals with a wide range of variable flow rates, integrated reverse osmosis water filtration, and an intuitive, easy-to-use graphical user interface, Diality says in a press release.
The Moda-flx haemodialysis system provides clinicians the flexibility to easily customise each haemodialysis experience according to patient needs in one integrated, smart system. The platform’s compact footprint and mobility enable seamless integration and transportation within dialysis care settings.
“Our partnership with the North America Research Institute is an important step toward delivering on our promise to improve the lives of patients and families affected by kidney disease,” said Osman Khawar, CEO of Diality. “This is the first of many patients who will enjoy a better dialysis experience with the Moda-flx haemodialysis system.”
“New kidney care technology, especially innovative technology such as the Moda-flx haemodialysis system, which allows us to personalise dialysis prescriptions to the needs of our patients, is exactly what the industry needs,” said Aamir Jamal, CEO of North America Research Institute. “The clinical flexibility the Moda-flx haemodialysis system offers dialysis providers is liberating. We can choose the right prescription for our patients and trust that the system will be able to deliver the therapy our patients need.”
The Moda-flx haemodialysis system is indicated for use in patients with acute and/or chronic renal failure, with or without ultrafiltration, in an acute, post-acute, or chronic care facility. Treatments must be administered under a physician’s prescription, by a trained person who is considered competent in the use of the device. Treatment types available include: intermittent haemodialysis (IHD), sustained low efficiency dialysis (SLED/SLEDD), and prolonged intermittent renal replacement therapy (PIRRT).